病毒療法對膠質母細胞瘤有效 Viral therapy highly effective at treating glioblastoma

中文版谷歌中文翻譯(90% 準確率) | English translation
Buy/Sell Your Domains Here。在這裡購買/出售您的域名
Contact Dr. Lu for information about cancer treatments。聯繫盧博士,獲取有關癌症治療資訊。

A report posted on February 13,  2019 on AMED.go.jp indicates that a viral therapy can be very effective at treating glioblastoma, a malignant brain tumor which is extremely aggressive and the median survival time was 18 months with the five year survival rate as low as 10%.

The viral therapy developed by Professor Tokinori Todo at the University of Tokyo was tested in 13 patients with diagnosed glioblastoma.  As a result, 92.3% patients who received treatment with this viral therapy survived in the first year. In comparison, the first year survival rate of patients who received conventional treatments was only 15%.

Side effects were mild and only manageable fever was observed in a couple of patients receiving the viral therapy.  The treatment has no effect on healthy cells and it kills only the cancer cells.

The viral therapy was based on herpes labialis virus or herpes simplex virus type 1 with three genes artificially modified. It was named as herpes virus G47Δ.

A petition was launched to get the viral therapy to the market as soon as possible so that cancer patients can use it to defeat their diseases.

病毒療法對膠質母細胞瘤有效

2019年2月13日在AMED.go​​.jp上發布的一份報告表明,病毒療法可以非常有效地治療膠質母細胞瘤,這是一種具有極強侵襲性的惡性腦腫瘤,中位生存時間為18個月,五年生存率為低至10%。

由東京大學Tokinori Todo教授開發的病毒療法在13例診斷為膠質母細胞瘤的患者中進行了測試。結果,接受這種病毒療法治療的患者中有92.3%在第一年存活。相比之下,接受常規治療的患者的第一年生存率僅為15%。

副作用較輕,在接受病毒治療的幾例患者中僅觀察到可控制的發燒。該療法對健康細胞沒有影響,並且僅殺死癌細胞。

病毒療法是基於人工改良的三個基因的唇皰疹病毒或1型單純皰疹病毒。它被命名為皰疹病毒G47Δ。

發起了一份請願書,將病毒療法盡快推向市場,以便癌症患者可以使用它來戰勝疾病。

$$$ If you are interested in a writer or editor position, check out here.We are hiring. $$$

44